Physician profile
John Hyland
NPI 1447221429
$1,095.09
in general payments reported to CMS, 2019-2025
28 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $106 · 2022: $102 · 2023: $210 · 2024: $195 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $143.03 | 2019-2024 | Xtandi, Vyloy |
| Eisai INC. | $113.31 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $95.35 | 2023-2025 | Calquence |
| Exelixis INC. | $76.11 | 2019-2025 | Cabometyx |
| Incyte Corporation | $59.79 | 2022-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $52.42 | 2019-2024 | |
| Celgene Corporation | $50.62 | 2019-2020 | |
| Seagen INC. | $41.32 | 2019-2023 | Padcev |
| Abbvie INC. | $29.42 | 2025 | |
| Daiichi Sankyo INC. | $28.91 | 2025 | Enhertu |
| Tesaro, INC. | $28.27 | 2019 | |
| Adaptive Biotechnologies Corporation | $25.31 | 2024 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $21.98 | 2023 | Libtayo |
| Clovis Oncology, INC. | $21.87 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $20.07 | 2024 | |
| Sumitomo Pharma America, INC. | $20.00 | 2023 | Orgovyx |
| Agios Pharmaceuticals, INC. | $18.94 | 2024 | Pyrukynd |
| Medtronic USA, INC. | $18.85 | 2020 | |
| Amgen INC. | $18.24 | 2023 | Xgeva, Vectibix, Nplate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2019 | |
| Foundation Medicine, INC. | $15.41 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2019 | |
| Genentech USA, INC. | $14.83 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.95 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.51 | 2024 | Alunbrig |
| Merck Sharp & Dohme LLC | $12.94 | 2020 | |
| Boston Scientific Corporation | $12.88 | 2023 | Rezum Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hyland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.